Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan

Journal of Dermatology

Volumn 39, Issue 3, 2012, Pages 269-273

  Cho, Yung Tsu ^a   Chen, Chien Hung ^a   Chiu, Hsien Yi ^a   Tsai, Tsen Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

hepatitis B virus; psoriasis; psoriatic arthritis; reactivation; tumor necrosis factor

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; ETANERCEPT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC DISEASE; CLINICAL ARTICLE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MALE; PSORIASIS; PSORIATIC ARTHRITIS; TAIWAN; TREATMENT DURATION; VIRUS CARRIER; VIRUS LOAD; VIRUS REACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; ARTHRITIS, PSORIATIC; CARRIER STATE; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TAIWAN; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84857657384     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01434.x     Document Type: Article

References (27)

1. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022. (Pubitemid 37448924)
2. Michel M, Duvoux C, Hezode C, Cherqui D,. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003; 30: 1624-1625. (Pubitemid 36835467)
3. Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64: 788-789. (Pubitemid 40559316)
4. Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008; 43: 397-401. (Pubitemid 351958904)
5. Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28: 718-720.
6. Fotiadou C, Lazaridou E, Ioannides D,. Safety of anti-tumor necrosis factor-alpha agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol 2011; 25: 471-474.
7. Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009; 36: 1188-1194.
8. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010; 69: 1352-1355.
9. Nosotti L, Francesconi F, Izzi S, Berardesca E, Morrone A, Bonifati C,. Safety of antitumor necrosis factor-alpha therapy in psoriatic patients with hepatitis B virus infection. Br J Dermatol 2010; 162: 1408-1410.
10. Raftery G, Griffiths B, Kay L, Kane D,. Chronic viral hepatitis and TNF-alpha blockade. Rheumatology (Oxford) 2007; 46: 1381; author reply -2. (Pubitemid 47244524)
11. Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken) 2010; 62: 749-754.
12. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
13. Hwang EW, Cheung R,. Global epidemiology of Hepatitis B virus (HBV) infection. NAJMS 2011; 4: 7-13.
14. Kohrt HE, Ouyang DL, Keeffe EB,. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007; 11: 965-991. (Pubitemid 350019026)
15. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-528. (Pubitemid 351665421)
16. Calabrese LH, Zein NN, Vassilopoulos D,. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983-989. (Pubitemid 44133258)
17. Domm S, Cinatl J, Mrowietz U,. The impact of treatment with tumor necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217-1228.
18. Carroll MB, Forgione MA,. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010; 29: 1021-1029.
19. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63: 40-46.
20. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
21. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
22. Bathon JM, Cohen SB,. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road. Arthritis Rheum 2008; 59: 757-759. (Pubitemid 351847557)
23. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850. (Pubitemid 351509656)
24. Hellan Kwon, Anna S,. Lok. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 275-284.
25. Feld JJ, Ayers M, El-Ashry D, et al. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2007; 46: 1057-1070. (Pubitemid 350147802)
26. Chisari FV,. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis. B Am J Pathol 2000; 156: 1117-1132.
27. Carroll MB, Bond MI,. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008; 38: 208-217.